Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Differential expression of the miRNA level in the serum from controls and OA patients analyzed by quantitative real-time PCR

From: Association of circulating microRNAs with prevalent and incident knee osteoarthritis in women: the OFELY study

miRPrevalent OA (−), median (IQR 25–75%)Prevalent OA (+), median (IQR 25–75%)p valueIncident OA (−), median (IQR 25–75%)Incident OA (+), median (IQR 25–75%)p value
126-3p1.08 (0.85–1.36)1.06 (0.89–1.30)0.750.89 (0.80–1.04)0.91 (0.73–1.23)0.66
12990.28 (0.16–1.73)0.33 (0.16–2.35)0.800.27 (0.14–11.36)0.34 (0.12–0.90)0.82
132-3p1.37 (0.71–2.12)0.86 (0.43–1.85)0.120.91 (0.63–1.19)1.04 (0.59–1.97)0.70
139-5p1.50 (0.34–3.63)2.09 (0.23–8.24)0.270.28 (0.05–1.98)0.81 (0.14–6.59)0.16
146a-5p0.85 (0.62–1.03)1.12 (0.73–1.46)0.0150.83 (0.70–0.97)0.88 (0.62–1.29)0.94
16-5p0.92 (0.72–1.82)0.85 (0.61–1.50)0.350.98 (0.59–1.24)1.01 (0.73–1.44)0.33
1840.95 (0.64–2.18)1.05 (0.58–2.38)0.860.69 (0.41–1.76)0.80 (0.31–1.24)0.89
186-5p1.09 (0.81–1.39)1.03 (0.79–1.31)0.470.82 (0.72–1.09)1.05 (0.82–1.46)0.09
195-5p0.91 (0.75–1.42)0.90 (0.52–1.60)0.500.93 (0.65–1.24)1.03 (0.69–1.47)0.42
199a-3p0.96 (0.77–1.12)0.93 (0.82–1.47)0.460.89 (0.76–0.98)1.00 (0.71–1.39)0.13
200a-3p0.84 (0.56–1.93)1.00 (0.58–1.57)0.620.72 (0.49–1.06)0.73 (0.48–1.43)0.93
29a-3p1.12 (0.76–1.44)1.00 (0.68–1.38)0.401.12 (0.63–1.35)0.84 (0.61–1.50)0.66
29b-3p1.14 (0.81–1.74)1.06 (0.81–1.51)0.381.02 (0.71–1.42)0.99 (0.67–1.53)0.93
29c-3p1.04 (0.66–1.59)0.91 (0.64–1.59)0.630.73 (0.44–1.16)0.86 (0.45–1.56)0.35
345-5p3.10 (0.10–10.01)2.81 (0.22–7.12)0.990.53 (0.05–2.11)1.14 (0.09–5.97)0.24
3751.57 (0.20–4.05)1.40 (0.48–4.77)0.560.98 (0.26–2.99)0.86 (0.24–3.07)0.91
885-5p1.40 (0.60–2.16)1.16 (0.28–2.40)0.480.97 (0.49–2.85)1.54 (0.70–2.38)0.54
93-5p1.11 (0.79–1.51)0.91 (0.68–1.38)0.211.07 (0.79–1.17)1.19 (0.79–1.53)0.25
let-7e-5p1.15 (0.41–4.52)2.28 (0.64–5.83)0.251.36(0.78–2.72)1.37 (0.36–2.36)0.89
  1. The miRNA levels were analyzed in the serum from individuals of the validation cohort, and differences in the serum miRNA levels are reported according to the prevalent or incident OA status. The relative miRNA level was used for the statistical comparisons. IQR = interquartile range [(+) = women with prevalent or incident knee OA, (−) = controls]